Other putative glucose-lowering therapies Insights from genomics, particularly the many genetic variants associated with type 2 diabetes, and from metabolomics and bioinformatics have indicated further potential therapeutic targets, but as yet these have not led to specific pharmacological interventions [90]
Large real-world study (2024): In 83,825 patients with obesity, semaglutide was associated with a ~50% lower risk of new or recurrent AUD compared with other anti-obesity meds over 12 months
Reflux, belching, nausea, and fullness can occur without gastroparesis
Eat nutritious foods Focus on foods rich in vitamin C (oranges, kiwis, tomatoes), vitamin E (almonds, avocados), and omega-3 (salmon, nuts)
3,4 Both strategies are utilized to augment the incretin effect, but there are key clinical differences among the DPP-4 inhibitors and GLP-1 receptor agonists